Bone health in juvenile idiopathic arthritis compared with controls based on a Norwegian observational study
- PMID: 40537274
- PMCID: PMC12182186
- DOI: 10.1136/rmdopen-2025-005605
Bone health in juvenile idiopathic arthritis compared with controls based on a Norwegian observational study
Abstract
Background: Children with juvenile idiopathic arthritis (JIA) are at risk for impaired bone health. This study evaluates bone mineral density (BMD) and potential risk factors for reduced BMD.
Methods: In the NorJIA study, Norwegian children with JIA, and age-matched and sex-matched controls participated in a multicentre cohort study with clinical examinations, questionnaires, imaging and blood tests. BMD was measured using dual-energy X-ray absorptiometry and adjusted for bone age. Standard descriptive statistics and t-tests were used.
Results: 205 children with JIA had BMD measured at two study visits, 2 years apart and 125 controls at the second visit. At visit 2, median age was 14.7 years (IQR 11.5-16.6). Median disease duration was 6.6 (IQR 4.7-10.4) years, 50.7% had used or were currently using biologic disease-modifying antirheumatic drugs and 25.9% had ever used systemic steroids. There were no substantial differences in BMD Z-scores between the JIA group and controls. Mean BMD Z-score L1-L4 in JIA was 0.0 (95% CI -0.1, 0.1) and in controls 0.1 (95% CI -0.1, 0.3). A robust association was seen between physical activity levels and BMD. In children with JIA, the mean BMD Z-score L1-L4 was -0.3 (95% CI -0.6, 0.0) in the low-activity group and 0.2 (95% CI 0.0, 0.4) in the high-activity group, with a similar trend in controls. Children with JIA were as physically active as controls.
Conclusions: BMD Z-scores in JIA were similar to controls and positively associated with physical activity. This underlines the importance of early disease control, steroid-sparing medications and physical activity to optimise bone health.
Trial registration number: NCT03904459.
Keywords: Arthritis, Juvenile; Bone Density; Child.
© Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY. Published by BMJ Group.
Conflict of interest statement
Competing interests: None declared.
Figures


Similar articles
-
A systematic review of the effectiveness of strategies for reducing fracture risk in children with juvenile idiopathic arthritis with additional data on long-term risk of fracture and cost of disease management.Health Technol Assess. 2008 Mar;12(3):iii-ix, xi-xiv, 1-208. doi: 10.3310/hta12030. Health Technol Assess. 2008. PMID: 18284894
-
Summary of AHRQ's Comparative Effectiveness Review of Disease-Modifying Antirheumatic Drugs for Children with Juvenile Idiopathic Arthritis.J Manag Care Pharm. 2012 Jan-Feb;18(1 Suppl B):1-16. doi: 10.18553/jmcp.2012.18.S1-B.1. J Manag Care Pharm. 2012. PMID: 22376227 Free PMC article.
-
The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation.Health Technol Assess. 2016 Apr;20(34):1-222. doi: 10.3310/hta20340. Health Technol Assess. 2016. PMID: 27135404 Free PMC article.
-
Nutritional interventions for survivors of childhood cancer.Cochrane Database Syst Rev. 2016 Aug 22;2016(8):CD009678. doi: 10.1002/14651858.CD009678.pub2. Cochrane Database Syst Rev. 2016. PMID: 27545902 Free PMC article.
-
Two-year follow-up study (PRIMROSE 3) to assess bone mineral density in subjects with uterine fibroids completing the PRIMROSE 1 and PRIMROSE 2 linzagolix trials.Hum Reprod Open. 2025 May 13;2025(3):hoaf025. doi: 10.1093/hropen/hoaf025. eCollection 2025. Hum Reprod Open. 2025. PMID: 40575397 Free PMC article.
References
-
- Petty RE, Southwood TR, Manners P, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision. J Rheumatol. 2001;31:390–2. - PubMed
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Medical